Purpose: Depressive and anxiety disorders are frequent among people with epilepsies. There are, however, only few longitudinal studies, which examine the relationship between these comorbid psychiatric disorders and epilepsy-related variables. Thus, we investigated the interrelationships of depression and anxiety symptoms with seizure frequency across time. Methods: Before admittance to an epilepsy center (T1) and six months after discharge (T2), patients (n = 198) with mainly difficult-to-treat epilepsies completed the Hospital Anxiety and Depression Scale (HADS). Correlation and path analyses were conducted. Results: Depression and anxiety symptoms (HADS) as well as seizure frequency significantly decreased from baseline to follow-up. Both at T1 and T2, seizure frequency was slightly, but significantly correlated with depression and anxiety levels (r s = 0.17-.32). Cross-lagged-analyses showed that baseline (T1) level of depression significantly predicted frequency of seizures at follow-up (T2). However, anxiety at T1 was not a significant predictor of seizure frequency at T2 and seizure frequency at T1 did not predict either depressive or anxiety symptoms at T2. Conclusion: The present findings emphasize the importance of psychiatric comorbidities, especially depression, for seizure frequency and its progress in patients with difficult-to-treat epilepsies referred to a specialized epilepsy center. Thus, comorbid psychiatric disorders need specific consideration as part of a comprehensive diagnostic and therapeutic treatment approach.
Introduction
People with epilepsies (PWE) show an increased prevalence of comorbid depressive and anxiety disorders with frequencies between 30% (in population-based samples) and 50% (in therapy-resistant samples) [1, 2] . In order to detect and treat depression and anxiety disorders in PWE [3, 4] , it is important to reveal and investigate variables associated with their modulation or with an increased risk for their development. Reviewing psychosocial predictors of depression and anxiety in PWE Gandy et al. [5] remarked: "Although cross-sectional studies are an important step for identifying predictors, they are limited to correlational inferences, such that causation cannot be inferred" (p. 229). So far, there are only few longitudinal studies examining the relationship between depression and anxiety with different influencing variables over time.
Endermann [6] examined 77 patients regarding different variables at their admission to an epilepsy center. Using regression analytical methods, the effectiveness of antiepileptic drugs (AED) rated by the physicians and the depressive symptoms at admission (Z-D, Zerssen's D-scale) predicted 48% of variance of depression at discharge.
Reisinger and Dilorio [7] also used multiple regression analyses for prediction of depressive symptoms (CED, Center for Epidemiological Studies -Depression Scale) by different baseline variables at study begin as well as after three and six months follow up. In a sample of 319 inpatients, employment status, social support, and epilepsy-related stigma emerged as predictors of depression scores at all three time points. However, the regression models did not control for baseline depression and no measure of seizure frequency was included, although it has been found to be associated with depression in prior studies [8, 9] .
Thapar et al. [10] explicitly examined the interrelationship between depressive symptoms and seizure frequency in a community-based sample (n = 976). All PWE were sent questionnaires, including the Hospital Anxiety and Depression Scale (HADS) to assess depression symptoms, and the Liverpool Quality of Life questionnaire, from which the information on seizure frequency (none,<1/month, !1/month) was taken. The authors found that depressive symptoms and seizure frequency were predictors of each other at both time points one year apart. Furthermore, cross-lagged analysis showed that depression scores at the first assessment predicted seizure frequency at the second assessment and, vice versa, seizure frequency at the first assessment predicted depression scores at the second assessment. This result demonstrated a bidirectional interrelationship between the two variables.
In a further study with PWE from general practices (n = 433), Thapar et al. [11] reported that baseline depression scores (HADS-D) predicted a change in seizure recency (time since last seizure) and frequency after five months. A predictive association was also demonstrated for baseline anxiety symptoms (HADS-A) and a five months later change in seizure recency and frequency, but it was mediated by depression. The reversed prediction of anxiety symptoms through baseline seizure frequency has not been considered further.
Aim of this study
Patients referred to an epilepsy center are predominantly characterized by long-lasting, difficult-to-treat epilepsies. Improving seizure control is a main treatment goal, e.g. by modifying the AED regime [12] . A majority of these patients also exhibits psychiatric comorbidities, which could compromise quality of life and treatment response [13] . As a secondary analysis of data gained in a broader epilepsy center evaluation survey [14] , the present study examined the interrelationships between depressive or anxiety symptoms and seizure frequency before and after inpatient treatment. Given the recent discussion on reproducibility difficulties in science [15, 16] , we wanted to re-examine and extend the results of Thapar et al. [10] in a sample of epilepsy inpatients. We hypothesized that a) patients' depression level prior to treatment predict seizure frequency subsequent to discharge and vice versa as well as b) anxiety symptoms at admission predict seizure rates after inpatient treatment and vice versa.
Methods

Patients
Four German diaconal epilepsy centers (Bethel, Bielefeld; Hephata, Schwalmstadt-Treysa; Kork, Kehl-Kork; and Kleinwachau, Radeberg) consecutively included patients, according to the following criteria: planned inpatient, non-surgical treatment because of a verified epileptic disorder, age !16, able to answer questionnaires independently or with assistive support. Patients with only non-epileptic seizures, insufficient German language skills or cognitive impairments, which constrain the completion of questionnaires, were excluded. The ethics committee of the University of Muenster, Germany, approved the study protocol.
Study design and procedure
The underlying evaluation survey was carried out as a prospective, multicenter, pre-post-design study [14] . Patients were asked to complete a questionnaire, send by mail, before admission to the center (T1, pre-measurement) and also 6 months after discharge (T2, follow-up).
Instruments
Depressive and anxiety symptoms
Depressive and anxiety symptoms were assessed by the German Version of the Hospital-Anxiety-and-Depression-Scale (HADS, [17] ). It comprises 2 subscales (anxiety: HADS-A, depression: HADS-D) with 7 items each. Subscale-scores are interpreted as following:<7 = normal range, 8-10 = borderline, !11 = probable presence of a clinical relevant depressive and/or anxiety disorder [18] . The HADS is a widely established instrument to screen for depression and/or anxiety symptoms [19] and has been evaluated in PWE [20, 21] .
Clinical and demographic data
The PESOS questionnaire (Performance, Sociodemographic aspects, Subjective evaluation, [22] ) was applied to obtain patients demographic, psychosocial and epilepsy-related information. Patients were asked how often they had seizures given the following selection options: 1 seizure per day or more, 1 seizure per week or more, 1-2 seizures per month, 3-5 seizures in the last 6 months, 1-2 seizures in the last six months, no seizures in the last 6 months (see Table 1 ). The PESOS has been used to assess subjective and objective information regarding individual impairments due to epilepsy in various studies (e.g. [23, 24] ).
Data analysis
At first, Pearson and Spearman correlation coefficients were used to describe the associations of seizure frequency with depression and anxiety symptoms for each time point and among time points.
Pathanalytical cross-lagged-models (which are an extension of multiple regression [25] ) were performed, referring to the statistical method used in the aforementioned Thapar et al. study [10] . This means that depression (or anxiety) scores and seizure frequency at T1 were assumed to predict each converse measure at T2, while controlling for autoregression effects. This statistical procedure is considered as one of the standard methods to analyse longitudinal data [26] . A post-hoc power analysis [27] Descriptive statistics, correlations, and regression analyses were performed using IBM SPSS Statistics (Version 21.0. Armonk, NY: IBM Corp.). Cross-lagged-models were analysed with Mplus 7.0 [29] . The significance level was set to a = 0.05 (two-tailed).
Results
Response and included patients
Altogether, 550 questionnaires were sent to patients expecting admission at one of the four epilepsy centers. Nearly 75% (n = 409) have been sent back, of which 107 had to be excluded due to violations of in-or exclusion criteria (unconfirmed epilepsy diagnosis: n = 38, no hospital admission: n = 25, indications on proxy ratings: n = 20) or too many missing responses overall (n = 24). Of the remaining 302 returns, both the T1-and T2-questionnaire was available in 198 cases ("responders"). The nonresponders (n = 104), who just answered at T1, were statistically comparable to the responders regarding several demographic, epilepsy-related and psychosocial characteristics (all p > 0.05); thus, a selection bias appears to be rather unlikely. Table 1 shows demographic and clinical characteristics of the sample at T1. As expected, seizure frequency was relatively high. The length of inpatient stay was 33.3 AE 29.0 days on average (n = 16 missing).
Sample characteristics
Characteristics of the target variables 3.3.1. Seizure frequency
Missing values in seizure frequency appeared relatively often across both time points (n = 41/198, 21%; T1: n = 10, T2: n = 26, T1 + T2: n = 5). Taking into account the date of the last seizure (from the PESOS questionnaire) and a three categorical classification (no,<1 or !1 seizure per month, cf. [10, 30] ), the number of evaluable cases could be increased from 157 to 187 patients (n = 11/ 198 missing, 5.5%). There was a significant reduction in seizure frequency from T1 to T2 (see Table 2 ).
Depression and anxiety symptoms: The rate of HADS-D scores !11 decreased from 28% at T1 to 13% at T2 (see Table 2 ). HADS-A scores !11 were found in 25% of the patients at T1 an in 19% at T2. Scores !11 in both of the HADS-subscales dropped from 15% at T1 to 6% at T2.
Correlations of seizure frequency with depression and anxiety
As shown in Table 3 , all correlations of seizure frequency with HADS-D (r s = 0.18-.32) and with HADS-A (r s = 0.17-.21) were statistically significant.
Cross-lagged-analyses
According to procedures applied by Thapar et al. [10] , HADSscores were considered as continuous variable and seizure frequency was included as an ordinal variable (three categories) into the cross-lagged-analyses. The multivariate method of structural equation modelling allows for the estimation of correlation structures between different scaled types of variables, Table 2 Depressive and anxiety symptoms and distribution of seizure frequency before admission (T1) and 6 months after discharge from epilepsy center (T2).
T1 T2
HADS-Depression (mean AE SD), n = 189 7. Table 1 ) were recoded as follows: !1 seizure per day, !1 seizure per week, and 1-2 seizures a month = < 1 seizure/month; 1-2 seizures and 3-5 seizures in the last 6 months = !1 seizure/month. within a common (cross-lagged-)model. Therefore, the robust WLSMV-(weighted least squares mean-and variance-adjusted) estimator implemented in Mplus was applied. The WLSMVestimator has been suggested for the analyses of small-scaled ordinal variables as well as smaller samples sizes [31] .
As shown in Fig. 1 , in the cross-lagged-analysis of depressive symptoms and seizure frequency, depression scores at T1 significantly predicted seizures frequency at T2 (p = 0.039). Seizure frequency at T1 showed no significant cross-lagged-association with depressive symptoms at T2 (p = 0.317).
In the cross-lagged-analysis of the association between anxiety symptoms (at T1 predicting seizure frequency at T2: p = 0.074) and seizure frequency (at T1 predicting anxiety scores at T2: p = 0.219) no significant cross-lagged relation appeared (see Fig. 2 ).
As Mplus specifies pairwise deletion of missing cases by default in appliance of WLSMV-estimation, we repeated all analyses under listwise deletion setup (n = 181), revealing comparable results. 
Discussion
This study aimed to re-examine and extend prior findings of reciprocal relationships between depressive or anxiety symptoms and seizure frequency in PWE. In particular, it was hypothesized that patients level of depression or anxiety before an epilepsy center treatment predicts seizure frequency subsequent to discharge and vice versa, i.e. seizure frequency before inpatient treatment predicts depression symptoms at follow up.
Effects of the treatment in epilepsy centers
There was a significant reduction in seizure frequency and nearly a quarter of the patients (n = 41/174), who had not been initially seizure-free, did not report any seizures at follow-up. In agreement with other studies [32, 33] , this indicates that improved seizure control or even seizure freedom is possible in some patients with difficult-to-treat epilepsies after referral to a specialized epilepsy center.
Furthermore, the rate of patients with clinically relevant depression or anxiety scores significantly decreased after inpatient treatment (p < 0.001). Overall, the prevalence of clinically relevant Note: Pearson-correlation coefficients are shown except for seizure frequency (=Spearman-correlation coefficient); Depression = HADS-D; Anxiety = HADS-A. *** p < 0.001. ** p < 0.01. * p < 0.05. Fig. 1 . Results of the cross-lagged-analysis including depression and seizure frequency. Fig. 2 . Results of the cross-lagged-analysis including anxiety and seizure frequency.
1 These results were approved by an additionally performed regression analyses (see figure A1 in the supplemental online material).
HADS-scores at follow-up was then almost comparable to PWE in general practices (HADS-D: 11.2%, HADS-A: 20.5%, [34] ).
Correlative relationships
Our findings on bivariate correlations demonstrate significant relationships of depressive and anxiety symptoms with seizure frequency before, across and after inpatient treatment. According to common conventions [28] , the strength of associations between depression scores and seizure frequency was small to moderate (r s = 0.18-.32) and the correlations between anxiety symptoms and seizure frequency were small (r s = 0.17-.21). Our results are in line with findings of other studies [8, 9, 35] , whereas some prior studies did not find associations between seizure frequency and depression [36] or anxiety symptoms [37] . Differing results might be attributable to varying patient samples and measurement instruments.
Bidirectional associations across time
Testing the hypothesis of a bidirectional association between psychiatric symptoms and seizure frequency, we only found the level of depression to be predictive of seizure frequency in the cross-lagged-analyses. Thus, regarding our presumptions derived from the study by Thapar et al. [10] , no bidirectional relationship between seizure rate and depression was observed in the present study. However, some methodological differences have to be considered, which might have caused differing results. For example, our study involved patients with long-lasting, difficultto-treat epilepsies, whereas Thapar et al. investigated a generalpractitioner-based sample and aimed to evaluate a prompt and reminder card. In their study, seizure status was measured slightly different and was also lower at the beginning and the end of the study (!1 seizure/month in the last year: T1 = 27.5%, T2 = 24.4%) compared to our inpatient group (!1 seizure/month in the last half-year: T1 = 55.6%, T2 = 35.3%). Besides the sample size difference (n = 198 vs. n = 976) both studies also differed in their interval between first and second examination (6 months vs. Thapar et al.: 12 months), this might have caused varying processes of change across time.
Contrary to depressive symptoms, anxiety symptoms showed no predictive association with seizure frequency in the current study. Therefore, we could not replicate one result of the 2009 study by Thapar et al. [11] in which the initial HADS-A score significantly predicted a change in seizure frequency five months later. These different results could be due to some differences in the characteristics of the earlier study, like a larger sample size (n = 433), a community-based sample and a lower proportion of people with frequent seizures (!1 seizure/month: 25.4%). In the present cross-lagged-model, there was merely an indication of a connection between anxiety symptoms and seizure frequency considering the path-coefficient and its marginal significance level of p=0.074.
The missing effect of baseline seizure frequency on depressive and anxiety symptoms at follow-up should be interpreted in the light of a generally minor influence of seizure related parameters on psychological impairments in PWE compared to, for instance, employment status or social support [7, 37, 38] . In a study by Mensah et al. [38] the addition of "seizure activity" to a regression model with employment status, AED side effects and other health problems as dependent variables increased the declared variance (R 2 = 0.278) of HADS-D scores just by 0.7%.
Clinical implications
In our study, depressive symptoms prior to inpatient treatment appeared to be a predictor for seizure frequency six months after discharge. This underlines the importance of comorbid depression symptoms on the seizure situation and its further progress. It is in line with earlier studies, which demonstrated the impact of depressive symptomatology on seizure control [39, 40] . For instance, Hitris et al. [39] had found that newly diagnosed PWE with a psychiatric comorbidity, particularly depression, showed a roughly two-fold increased risk of still having seizures in the follow-up examination 20 years later compared to those without depression. Concerning the relationship between psychiatric disorders and epilepsy a " . . . potential role of pathogenic mechanisms of mood disorders in the development of epileptic seizures and epileptogenesis" is currently being discussed [41] . We found only the depression level to be predictive of seizure frequency. This could underline the assumption that depressive disorders cause neuro-chemical, structural and/or neuropathologic abnormalities that facilitate the development of a hyperexcitable cortex, what then may lead to a worse seizure frequency outcome (see [42] ).
Additionally, the impact of depressive symptoms on seizure control as well as the correlations of seizure frequency with depression and anxiety scores points out to the need for a differential diagnosis and appropriate treatment of psychiatric impairments in PWE ( [3, 4] ).
Limitations
Some limitations should be considered. First, the sample was ascertained through epilepsy centers and, therefore, the results could not directly be generalized to other patient groups, (e.g., community samples with less complicated epilepsies). Since depressive and anxiety disorders tend to frequently co-occur in PWE [13] , future studies should examine their interrelated influence on epilepsy-related variables. Moreover, it is of interest whether other factors (e.g. length of patients stay or demographic factors, like employment or age) among depression symptoms are significant predictors of seizure frequency. For instance, we did not consider possible effects of the AED treatment. However, results of the underlying survey [14] have shown that the number of different seizures types and of AEDs at admission are predictors of clinically relevant seizure reduction. Future studies should also explore the treatment duration as a possible influential factor on the interaction of seizure related and psychological treatment outcomes.
Furthermore, it should be taken into account that all results are based on self-report, whereas especially the accuracy of patient seizure counts has been questioned [43] . Regarding the psychological assessment it is worth mentioning that the HADS is just a screening instrument [16] . A definitive diagnosis meeting DSM criteria of depression or anxiety disorder has to rely on a comprehensive clinical examination [44] , what was out of scope for the underlying study.
The percentage of missing data was comparatively low, but we cannot exclude that it may have biased the present results, as we did not apply a certain missing-data method (e.g., multiple imputation [45] ). Moreover, only manifest (really measured) variables were used and, therefore, model estimations did not comprise any measurement error compared to other modelling approaches for analyzing longitudinal data (e.g. [46] ).
Conclusions
Results of the present study highlight that seizure frequency is correlated with anxiety and depression symptoms in PWE both before and after treatment in a specialized epilepsy center. Moreover, the self-rated depression level before admission is significantly related to seizure frequency six months after inpatient treatment. This underlines the impact of comorbid psychiatric problems on the seizure situation.
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